<DOC>
	<DOCNO>NCT00033943</DOCNO>
	<brief_summary>This study evaluate effectiveness safety experimental compound OP2000 ( deligoparin ) patient active ulcerative colitis . Patients eligible study receive ( continue receive ) stable dos aminosalicylates ( oral , enema and/or suppository ) , tolerate . OP2000 ultra low molecular weight heparin anticoagulant ( blood thin ) anti-inflammatory action may benefit treatment ulcerative colitis .</brief_summary>
	<brief_title>Safety Efficacy OP2000 ( Deligoparin ) Treatment Active Ulcerative Colitis</brief_title>
	<detailed_description>This double-blind , placebo-controlled , research study evaluate effectiveness safety experimental compound OP2000 ( deligoparin ) patient active ulcerative colitis . Patients eligible study receive ( continue receive ) stable dos aminosalicylates ( oral , enema and/or suppository ) , tolerate . OP2000 ultra low molecular weight heparin anticoagulant ( blood thin ) anti-inflammatory action may benefit treatment ulcerative colitis . Patients randomize ( assigned chance like toss coin ) receive 75 mg OP2000 , 125 mg OP2000 , placebo daily 6 week . Study drug administer subcutaneous ( skin ) injection patient teach self-administer injection . Following initial Screening Visit , eligible patient return clinic initiation study treatment follow-up visit 1 , 2 , 4 6 week treatment . A follow-up telephone call schedule 2 month ( possibly also 4 6 month ) complete study treatment . Study procedure include flexible sigmoidoscopy Screening Visit Week 6 visit .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>History ulcerative colitis least 3 month biopsy colonoscopy confirmation . Treatment aminosalicylates least 28 day , tolerate . Duration current flareup least 7 day . Must able self administer oncedaily subcutaneous ( skin ) injection study drug . Disease limit rectum . Toxic megacolon . The use anticoagulant drug . A history bleed disorder . A history heparininduced thrombocytopenia . Evidence liver kidney impairment . Women pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2002</verification_date>
</DOC>